FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research ANESTHETIC AND LIFE SUPPORT DRUGS ADVISORY COMMITTEE (ALSDAC) Holiday Inn, Ballrooms, 2 Montgomery Village Avenue, Gaithersburg, MD DRAFT AGENDA

January 30, 2002

8:00 a.m.	Call to Order and Introductions	Nathaniel P. Katz, M.D. Acting Chair, ALSAC
	Conflict of Interest Statement	Kimberly L. Topper Executive Secretary, ALSDAC
8:20 a.m.	Welcome and Introductory Comments	Cynthia McCormick, M.D. Director, Division of Anesthetic, Critical Care and Addiction
8:35 a.m.	Open Public Hearing	Drug Products (DACADP), FDA
9:50 a.m.	Introduction to Session I: Opiate Analgesic Development and Use	Bob Rappaport, M.D. Deputy Director, DACADP, FDA
10:00 a.m.	Pain Treatment Guidelines	Bruce Allen Levy, M.D., J.D.
10:30 a.m.	Treatment of Patients with Chronic Pain	Russell Portenoy, M.D. Department of Pain Medicine and Palliative Ca Beth Israel Medical Center
11:00 a.m.	Break	Detri israel medical Center
11:15 a.m.	Opiate Analgesic Trials and Drug Development Plans	Gerald DalPan, M.D. Medical Officer, DACADP, FDA
11:30 p.m.	Questions and Discussion	
12:30 p.m.	Lunch	
1:30 p.m.	Introduction to Session II Opiate Analgesic Use in Pediatric Patients	Bob Rappaport, M.D. Deputy Director, DACADP, FDA
1:45 p.m.	Pediatric Analgesic Use	Debra Friedman, M.D. University of Washington, Children's Hospital and Regional Medical Center
2:15 p.m.	Pediatric Exclusivity and the Pediatric Rule	Rosemary Roberts, M.D. Pediatrics Team, FDA
2:40 p.m.	Pediatric Opiate Analgesic Trials and Development Plans: Case Studies	Nancy Chang, M.D. Medical Officer, DACADP, FDA
3:00 p.m.	Questions and Discussion	
5:30 p.m.	Adjourn	